loxapine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
psychoactive 1613 1977-10-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • loxapine
  • loxapin
  • oxilapine
  • loxapine succinate
  • cloxazepine
  • loxitane
  • adasuve
  • loxapine hydrochloride
  • loxapine HCl
  • loxipine maleate
An antipsychotic agent used in SCHIZOPHRENIA.
  • Molecular weight: 327.81
  • Formula: C18H18ClN3O
  • CLOGP: 3.68
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 28.07
  • ALOGS: -3.50
  • ROTB: 0
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
9.10 mg Inhal.powder
0.10 g O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 30 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma) 0.02 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.474 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.302 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 38.548 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 44.361 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 3.360 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 9.340 % High 1
herg hERG pIC50 5.570 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 9.572 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 28.708 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 3.430 % High 1
kinase-safety-class ACVR2B,BRAF,CAMK2D,CDK5,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,PDK2,PDK4,PRKDC 12
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.378 High 1
mh-clint Mouse hepatocyte intrinsic clearance 106.660 High 1
mppb Mouse plasma protein binding (% unbound) 4.910 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.104 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 7.740 % High 1
rh-clint Rat hepatocyte intrinsic clearance 220.800 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 22.710 % High 1
rppb Rat plasma protein binding (% unbound) 4.540 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 81.470 uM High 1

Approvals:

DateAgencyCompanyOrphan
Feb. 25, 1975 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 687.89 41.46 237 5975 72395 90549840
Poisoning deliberate 675.68 41.46 168 6044 16318 90605917
Neuroleptic malignant syndrome 386.63 41.46 106 6106 14990 90607245
Extrapyramidal disorder 229.45 41.46 72 6140 16231 90606004
Somnolence 197.00 41.46 141 6071 208943 90413292
Altered state of consciousness 193.60 41.46 75 6137 31457 90590778
Oculogyric crisis 189.74 41.46 42 6170 2437 90619798
Substance use disorder 158.88 41.46 35 6177 1985 90620250
Hepatocellular injury 157.11 41.46 63 6149 28895 90593340
Miosis 150.75 41.46 46 6166 9438 90612797
Poisoning 137.02 41.46 48 6164 15169 90607066
Hypothermia 135.93 41.46 48 6164 15527 90606708
Intestinal obstruction 135.60 41.46 61 6151 37070 90585165
Cholestasis 133.73 41.46 60 6152 36239 90585996
Tachycardia 131.71 41.46 99 6113 157574 90464661
Drug use disorder 130.61 41.46 40 6172 8303 90613932
Faecaloma 125.86 41.46 41 6171 10390 90611845
Asphyxia 115.21 41.46 35 6177 7068 90615167
Hepatic cytolysis 113.54 41.46 51 6161 30865 90591370
Intentional overdose 106.27 41.46 71 6141 93763 90528472
Hyperprolactinaemia 102.11 41.46 30 6182 5403 90616832
Hypotension 101.63 41.46 118 6094 325279 90296956
Pneumonia aspiration 99.89 41.46 51 6161 40889 90581346
Wrong patient received product 96.29 41.46 26 6186 3451 90618784
Drug abuse 94.90 41.46 63 6149 82284 90539951
Rhabdomyolysis 94.54 41.46 53 6159 51203 90571032
Toxicity to various agents 94.25 41.46 107 6105 287739 90334496
Cardio-respiratory arrest 91.92 41.46 56 6156 63084 90559151
Drug reaction with eosinophilia and systemic symptoms 83.74 41.46 46 6166 42712 90579523
Drug interaction 80.84 41.46 97 6115 276356 90345879
Galactorrhoea 79.97 41.46 24 6188 4648 90617587
Catatonia 73.84 41.46 24 6188 6032 90616203
Choking 71.58 41.46 28 6184 12005 90610230
Benzodiazepine drug level increased 69.14 41.46 12 6200 191 90622044
Intestinal pseudo-obstruction 68.93 41.46 16 6196 1147 90621088
Victim of crime 67.96 41.46 15 6197 857 90621378
Subileus 67.94 41.46 20 6192 3624 90618611
Bradypnoea 67.26 41.46 21 6191 4637 90617598
Sedation 65.70 41.46 41 6171 48130 90574105
Depressed level of consciousness 61.31 41.46 46 6166 72738 90549497
Urinary retention 58.84 41.46 35 6177 37709 90584526
Hyperthermia 57.79 41.46 23 6189 10312 90611923
Salivary hypersecretion 57.07 41.46 22 6190 9070 90613165
Brain death 53.37 41.46 17 6195 4004 90618231
Hypoglycaemia 51.94 41.46 41 6171 69807 90552428
Disease recurrence 51.21 41.46 32 6180 37621 90584614
Amimia 49.81 41.46 8 6204 77 90622158
Suicide attempt 49.19 41.46 41 6171 75358 90546877
Fatigue 48.81 41.46 10 6202 1154013 89468222
Pulmonary embolism 48.52 41.46 52 6160 130768 90491467
Tardive dyskinesia 46.47 41.46 20 6192 10910 90611325
Antipsychotic drug level above therapeutic 46.19 41.46 12 6200 1372 90620863
Dystonia 44.06 41.46 22 6190 16797 90605438
Faecal vomiting 41.95 41.46 10 6202 804 90621431
Cardiogenic shock 41.58 41.46 24 6188 24444 90597791

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 524.28 38.06 258 10280 53296 42557501
Antipsychotic drug level below therapeutic 473.88 38.06 118 10420 3086 42607711
Therapeutic product effect variable 452.29 38.06 113 10425 2996 42607801
Disinhibition 451.00 38.06 118 10420 3777 42607020
Obsessive-compulsive disorder 408.40 38.06 123 10415 6620 42604177
Akathisia 390.60 38.06 132 10406 10319 42600478
Euphoric mood 387.74 38.06 117 10421 6336 42604461
Increased appetite 350.65 38.06 117 10421 8789 42602008
Poisoning deliberate 260.58 38.06 97 10441 10037 42600760
Suicide attempt 236.03 38.06 145 10393 45955 42564842
Neuroleptic malignant syndrome 229.25 38.06 110 10428 21362 42589435
Somnolence 229.13 38.06 224 10314 140881 42469916
Leukaemia 204.15 38.06 70 10468 5702 42605095
Extrapyramidal disorder 199.57 38.06 92 10446 16320 42594477
Miosis 190.91 38.06 84 10454 13362 42597435
Dyslipidaemia 153.91 38.06 65 10473 9353 42601444
Substance use disorder 147.80 38.06 54 10484 5291 42605506
Wrong patient received product 144.63 38.06 48 10490 3535 42607262
Therapeutic product effect incomplete 138.57 38.06 125 10413 70814 42539983
Drug use disorder 138.45 38.06 62 10476 10271 42600526
Rhabdomyolysis 137.91 38.06 130 10408 77889 42532908
Choking 135.64 38.06 53 10485 6245 42604552
Obesity 133.43 38.06 70 10468 16389 42594408
Faecaloma 132.34 38.06 52 10486 6218 42604579
Intestinal obstruction 130.18 38.06 82 10456 27076 42583721
Sedation 128.79 38.06 85 10453 30390 42580407
Leukopenia 127.24 38.06 122 10416 74624 42536173
Prescribed overdose 125.20 38.06 62 10476 12865 42597932
Weight increased 111.05 38.06 135 10403 107848 42502949
Hepatocellular injury 109.74 38.06 70 10468 23608 42587189
Drug abuse 104.51 38.06 129 10409 104642 42506155
Toxicity to various agents 102.35 38.06 194 10344 228942 42381855
Hypothermia 100.77 38.06 53 10485 12462 42598335
Altered state of consciousness 96.30 38.06 70 10468 29189 42581608
Schizoaffective disorder 94.14 38.06 30 10508 1940 42608857
Pneumonia aspiration 89.45 38.06 84 10454 49994 42560803
Drug interaction 85.22 38.06 197 10341 266802 42343995
Poisoning 84.82 38.06 50 10488 14649 42596148
Wrong patient 81.86 38.06 21 10517 618 42610179
Asphyxia 74.91 38.06 38 10500 8288 42602509
Congestive cardiomyopathy 67.39 38.06 36 10502 8728 42602069
Tachycardia 66.73 38.06 102 10436 100985 42509812
Product use in unapproved indication 66.48 38.06 143 10395 184313 42426484
Electrocardiogram QT prolonged 66.32 38.06 70 10468 47875 42562922
Eyelid function disorder 65.60 38.06 14 10524 179 42610618
Cogwheel rigidity 64.27 38.06 22 10516 1779 42609018
Bradypnoea 64.11 38.06 28 10510 4365 42606432
Subileus 63.22 38.06 26 10512 3495 42607302
Cardio-respiratory arrest 61.29 38.06 74 10464 58562 42552235
Parkinsonism 60.92 38.06 36 10502 10587 42600210
Hepatic cytolysis 59.73 38.06 51 10487 26793 42584004
Irritability 59.67 38.06 52 10486 28076 42582721
Dyspnoea 54.14 38.06 21 10517 442600 42168197
Mydriasis 53.67 38.06 31 10507 8739 42602058
Hyperleukocytosis 52.81 38.06 21 10517 2587 42608210
Dysphemia 51.77 38.06 19 10519 1883 42608914
Agitation 51.28 38.06 71 10467 64243 42546554
Fatigue 51.12 38.06 22 10516 435619 42175178
Colitis ischaemic 50.87 38.06 28 10510 7198 42603599
Confusional state 50.40 38.06 121 10417 167476 42443321
Pneumonia 50.03 38.06 21 10517 422128 42188669
Nausea 49.89 38.06 18 10520 396781 42214016
Catatonia 46.20 38.06 25 10513 6214 42604583
Hyperthermia 45.76 38.06 32 10506 12542 42598255
Diarrhoea 45.61 38.06 29 10509 460820 42149977
Aggression 44.94 38.06 55 10483 44108 42566689
Headache 44.55 38.06 4 10534 239365 42371432
Psychotic symptom 44.10 38.06 18 10520 2372 42608425
Blood creatine phosphokinase increased 44.09 38.06 57 10481 48281 42562516
Necrotising colitis 42.85 38.06 15 10523 1296 42609501
Asthenia 42.21 38.06 9 10529 280784 42330013
Pain 40.81 38.06 6 10532 244842 42365955
Wrong product administered 40.76 38.06 23 10515 6203 42604594
Weight decreased 40.00 38.06 3 10535 207945 42402852
Arthralgia 39.37 38.06 3 10535 205235 42405562

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 1223.22 32.55 495 14651 117374 110456779
Poisoning deliberate 888.24 32.55 267 14879 26064 110548089
Neuroleptic malignant syndrome 591.74 32.55 209 14937 33850 110540303
Somnolence 461.97 32.55 357 14789 297092 110277061
Extrapyramidal disorder 448.01 32.55 163 14983 28704 110545449
Miosis 363.04 32.55 130 15016 21853 110552300
Substance use disorder 311.88 32.55 89 15057 7201 110566952
Altered state of consciousness 285.59 32.55 145 15001 57481 110516672
Drug use disorder 272.67 32.55 100 15046 17974 110556179
Rhabdomyolysis 270.02 32.55 181 14965 120220 110453933
Faecaloma 268.29 32.55 94 15052 14814 110559339
Hepatocellular injury 264.34 32.55 132 15014 50510 110523643
Intestinal obstruction 258.12 32.55 132 15014 53095 110521058
Wrong patient received product 247.85 32.55 73 15073 6601 110567552
Hypothermia 239.61 32.55 101 15045 26201 110547952
Poisoning 220.09 32.55 98 15048 29007 110545146
Choking 218.32 32.55 81 15065 15029 110559124
Pneumonia aspiration 213.60 32.55 135 15011 81098 110493055
Drug abuse 205.57 32.55 180 14966 177231 110396922
Tachycardia 189.76 32.55 192 14954 226453 110347700
Asphyxia 186.45 32.55 71 15075 14144 110560009
Antipsychotic drug level below therapeutic 186.04 32.55 44 15102 1691 110572462
Akathisia 180.54 32.55 73 15073 17040 110557113
Drug interaction 178.55 32.55 276 14870 499907 110074246
Hepatic cytolysis 168.92 32.55 101 15045 54952 110519201
Therapeutic product effect variable 161.66 32.55 43 15103 2675 110571478
Disinhibition 160.21 32.55 44 15102 3090 110571063
Cardio-respiratory arrest 149.29 32.55 125 15021 115711 110458442
Oculogyric crisis 142.64 32.55 42 15104 3790 110570363
Subileus 140.83 32.55 47 15099 6390 110567763
Bradypnoea 134.66 32.55 49 15097 8600 110565553
Sedation 130.80 32.55 94 15052 69589 110504564
Suicide attempt 127.92 32.55 109 15037 103285 110470868
Catatonia 121.92 32.55 49 15097 11251 110562902
Obsessive-compulsive disorder 120.14 32.55 43 15103 7198 110566955
Toxicity to various agents 119.48 32.55 226 14920 480329 110093824
Euphoric mood 119.03 32.55 45 15101 8782 110565371
Electrocardiogram QT prolonged 111.16 32.55 103 15043 108857 110465296
Hyperthermia 106.66 32.55 54 15092 21218 110552935
Fatigue 102.76 32.55 21 15125 1215937 109358216
Urinary retention 99.80 32.55 80 15066 69603 110504550
Congestive cardiomyopathy 98.32 32.55 45 15101 14174 110559979
Schizoaffective disorder 97.85 32.55 30 15116 3106 110571047
Dyslipidaemia 96.38 32.55 46 15100 15919 110558234
Cholestasis 92.24 32.55 74 15072 64444 110509709
Parkinsonism 90.35 32.55 49 15097 22138 110552015
Increased appetite 89.95 32.55 43 15103 14934 110559219
Salivary hypersecretion 89.61 32.55 45 15101 17376 110556777
Intestinal pseudo-obstruction 87.55 32.55 28 15118 3328 110570825
Wrong patient 85.75 32.55 23 15123 1476 110572677
Pain 83.75 32.55 15 15131 954940 109619213
Intentional overdose 82.27 32.55 96 15050 132405 110441748
Agitation 80.57 32.55 88 15058 112963 110461190
Blood creatine phosphokinase increased 78.24 32.55 71 15075 73006 110501147
Depressed level of consciousness 77.59 32.55 86 15060 112192 110461961
Hyperleukocytosis 74.79 32.55 25 15121 3414 110570739
Hypotension 74.25 32.55 197 14949 523652 110050501
Cogwheel rigidity 73.01 32.55 25 15121 3673 110570480
Hyperprolactinaemia 72.62 32.55 29 15117 6546 110567607
Tardive dyskinesia 72.57 32.55 36 15110 13543 110560610
Arthralgia 71.08 32.55 11 15135 779621 109794532
Bladder dilatation 70.48 32.55 22 15124 2417 110571736
Necrotising colitis 68.57 32.55 20 15126 1745 110572408
Galactorrhoea 66.39 32.55 24 15122 4131 110570022
Drug reaction with eosinophilia and systemic symptoms 65.73 32.55 68 15078 82027 110492126
Wrong product administered 64.39 32.55 31 15115 10929 110563224
Faecal vomiting 61.96 32.55 18 15128 1548 110572605
Dyskinesia 61.06 32.55 53 15093 51393 110522760
Headache 60.01 32.55 23 15123 882354 109691799
Rash 59.95 32.55 19 15127 820945 109753208
Eyelid function disorder 59.41 32.55 14 15132 529 110573624
Leukaemia 59.00 32.55 26 15120 7492 110566661
Benzodiazepine drug level increased 58.45 32.55 12 15134 236 110573917
Irritability 58.26 32.55 50 15096 47759 110526394
Nausea 57.53 32.55 51 15095 1235639 109338514
Aggression 56.56 32.55 54 15092 59156 110514997
Mydriasis 56.12 32.55 36 15110 22121 110552032
Dyspnoea 54.81 32.55 43 15103 1106829 109467324
Respiratory acidosis 54.80 32.55 30 15116 13796 110560357
Pain in extremity 54.54 32.55 3 15143 487115 110087038
Confusional state 54.36 32.55 164 14982 468516 110105637
Sinus tachycardia 51.12 32.55 45 15101 44448 110529705
Victim of crime 50.78 32.55 15 15131 1368 110572785
Diarrhoea 50.68 32.55 49 15097 1139456 109434697
Distal intestinal obstruction syndrome 50.58 32.55 14 15132 1011 110573142
Drug hypersensitivity 50.21 32.55 3 15143 454087 110120066
Joint swelling 48.74 32.55 3 15143 442842 110131311
Colitis ischaemic 47.84 32.55 30 15116 17720 110556433
Psychomotor skills impaired 47.73 32.55 22 15124 7036 110567117
Dystonia 46.54 32.55 34 15112 25771 110548382
Trismus 45.99 32.55 21 15125 6575 110567578
Housebound 45.78 32.55 11 15135 452 110573701
Leukopenia 44.52 32.55 76 15070 148715 110425438
Amimia 43.91 32.55 8 15138 81 110574072
Generalised tonic-clonic seizure 43.23 32.55 45 15101 54635 110519518
Anterograde amnesia 43.23 32.55 12 15134 876 110573277
Psychotic symptom 42.51 32.55 17 15129 3850 110570303
Nasopharyngitis 42.43 32.55 3 15143 394358 110179795
Parkinsonian rest tremor 42.13 32.55 10 15136 390 110573763
Decreased appetite 40.50 32.55 8 15138 475838 110098315
Intestinal ischaemia 40.26 32.55 26 15120 16153 110558000
Camptocormia 40.15 32.55 10 15136 478 110573675
Respiratory depression 40.07 32.55 34 15112 31967 110542186
Brain death 39.85 32.55 19 15127 6554 110567599
Product use in unapproved indication 38.84 32.55 142 15004 447235 110126918
Antipsychotic drug level above therapeutic 38.63 32.55 14 15132 2426 110571727
Psychotic disorder 38.63 32.55 41 15105 50896 110523257
Dizziness 38.62 32.55 24 15122 698169 109875984
Alopecia 38.59 32.55 3 15143 364750 110209403
Disturbance in attention 38.58 32.55 45 15101 61950 110512203
Hypersensitivity 38.40 32.55 5 15141 403993 110170160
Respiratory distress 37.96 32.55 47 15099 68827 110505326
Death 37.68 32.55 192 14954 698677 109875476
Weight decreased 37.54 32.55 9 15137 468048 110106105
Pneumonia 37.43 32.55 39 15107 876675 109697478
Large intestine perforation 37.19 32.55 25 15121 16604 110557549
Hallucination, auditory 37.12 32.55 30 15116 26367 110547786
Cough 36.78 32.55 9 15137 461632 110112521
Drug intolerance 36.39 32.55 6 15140 406506 110167647
Psychiatric decompensation 35.98 32.55 17 15129 5748 110568405
Antipsychotic drug level increased 35.72 32.55 18 15128 6997 110567156
Myocarditis septic 35.71 32.55 6 15140 36 110574117
Infection 35.60 32.55 4 15142 362196 110211957
Bradycardia 34.67 32.55 70 15076 155447 110418706
Hepatitis acute 34.46 32.55 25 15121 18741 110555412
Compensatory sweating 34.20 32.55 6 15140 48 110574105
Swelling 34.20 32.55 4 15142 351037 110223116
Diabetic hyperosmolar coma 34.07 32.55 10 15136 892 110573261

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AH01 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Diazepines, oxazepines, thiazepines and oxepines
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014150 Antipsychotic Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018492 Dopamine Antagonists
CHEBI has role CHEBI:176497 geroprotector
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:48561 dopaminergic antagonist
CHEBI has role CHEBI:65023 anti-asthmatic agent

Related Drugs by ATC class:

N05AH Diazepines, oxazepines, thiazepines and oxepines 6 drugs
asenapineclotiapineclozapineolanzapinequetiapinesamidorphan

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Bipolar disorder indication 13746004 DOID:3312
Schizophrenia indication 58214004 DOID:5419
Alcoholism contraindication 7200002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Glaucoma contraindication 23986001 DOID:1686
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Tardive dyskinesia contraindication 102449007
Seizure disorder contraindication 128613002
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Coma contraindication 371632003
Carcinoma of female breast contraindication 447782002
Pigmentary Retinopathy contraindication
Drug Induced CNS Depression contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.59 Basic
pKa2 3.24 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 8.62 CHEMBL CHEMBL
D(2) dopamine receptor GPCR ANTAGONIST Ki 7.68 CHEMBL CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.82 PDSP
Sodium-dependent noradrenaline transporter Transporter Ki 5.24 PDSP
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 8 IUPHAR
5-hydroxytryptamine receptor 6 GPCR Ki 7.82 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 7.51 PDSP
Alpha-2B adrenergic receptor GPCR Ki 6.97 PDSP
D(3) dopamine receptor GPCR ANTAGONIST IC50 7.66 CHEMBL
D(1B) dopamine receptor GPCR Ki 7.13 PDSP
Histamine H1 receptor GPCR ANTAGONIST Ki 8.20 IUPHAR
Histamine H2 receptor GPCR Ki 6.68 PDSP
Histamine H4 receptor GPCR Ki 5.30 PDSP
Muscarinic acetylcholine receptor M1 GPCR IC50 5.26 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 6.38 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 6.91 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 6.09 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 6.83 PDSP
5-hydroxytryptamine receptor 1B GPCR Ki 6.41 PDSP
5-hydroxytryptamine receptor 1D GPCR Ki 5.46 PDSP
Alpha-2C adrenergic receptor GPCR Ki 7.10 PDSP
D(4) dopamine receptor GPCR ANTAGONIST Ki 8.31 CHEMBL
5-hydroxytryptamine receptor 3A Ion channel Ki 6.72 PDSP
Alpha-1B adrenergic receptor GPCR Ki 7.28 PDSP
5-hydroxytryptamine receptor 5A GPCR Ki 6.11 PDSP
5-hydroxytryptamine receptor 1E GPCR Ki 5.85 PDSP
Potassium channel subfamily K member 2 Ion channel IC50 4.70 CHEMBL
Potassium channel subfamily T member 1 Ion channel ACTIVATOR EC50 5.36 IUPHAR
5-hydroxytryptamine receptor 1A GPCR Ki 5.61 PDSP
D(1A) dopamine receptor GPCR Ki 7.27 PDSP
D(2) dopamine receptor GPCR Ki 7.68 CHEMBL
5-hydroxytryptamine receptor 2A GPCR IC50 8.22 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 7.37 CHEMBL
5-hydroxytryptamine receptor 2C GPCR IC50 6 CHEMBL
Histamine H1 receptor GPCR IC50 6 CHEMBL
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 7.80 IUPHAR
Adrenergic receptor alpha-1 GPCR IC50 7.74 CHEMBL

External reference:

IDSource
4019805 VUID
N0000147894 NUI
D00794 KEGG_DRUG
27833-64-3 SECONDARY_CAS_RN
4017917 VANDF
4017918 VANDF
4019805 VANDF
C0024056 UMLSCUI
CHEBI:50841 CHEBI
CHEMBL831 ChEMBL_ID
DB00408 DRUGBANK_ID
CHEMBL1201155 ChEMBL_ID
CHEMBL1201060 ChEMBL_ID
D008152 MESH_DESCRIPTOR_UI
3964 PUBCHEM_CID
205 IUPHAR_LIGAND_ID
2610 INN_ID
54810-23-0 SECONDARY_CAS_RN
LER583670J UNII
1364415 RXNORM
1308 MMSL
1346 MMSL
196711 MMSL
29026 MMSL
4999 MMSL
5000 MMSL
d00897 MMSL
001522 NDDF
001523 NDDF
001524 NDDF
1971003 SNOMEDCT_US
30745005 SNOMEDCT_US
372789006 SNOMEDCT_US
59270007 SNOMEDCT_US
LER583670J INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1394 CAPSULE 5 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1395 CAPSULE 10 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1396 CAPSULE 25 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0527-1397 CAPSULE 50 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0369 CAPSULE 5 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0370 CAPSULE 10 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0371 CAPSULE 25 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 0591-0372 CAPSULE 50 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 10135-585 TABLET 5 mg ORAL ANDA 19 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 10135-586 TABLET 10 mg ORAL ANDA 19 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 10135-587 TABLET 25 mg ORAL ANDA 19 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 10135-588 TABLET 50 mg ORAL ANDA 19 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 17856-1397 CAPSULE 50 mg ORAL ANDA 20 sections
Adasuve HUMAN PRESCRIPTION DRUG LABEL 1 51097-001 AEROSOL, POWDER 10 mg RESPIRATORY (INHALATION) NDA 31 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 62135-492 CAPSULE 5 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 62135-493 CAPSULE 10 mg ORAL ANDA 13 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 64850-890 CAPSULE 5 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 64850-891 CAPSULE 10 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 64850-892 CAPSULE 25 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 64850-893 CAPSULE 50 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 67046-1478 CAPSULE 25 mg ORAL ANDA 19 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 67046-1479 CAPSULE 5 mg ORAL ANDA 19 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 67046-1485 CAPSULE 10 mg ORAL ANDA 19 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 68151-2875 CAPSULE 5 mg ORAL ANDA 18 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-0346 CAPSULE 5 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-0416 CAPSULE 50 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-0416 CAPSULE 50 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-1681 CAPSULE 10 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-1792 CAPSULE 50 mg ORAL ANDA 20 sections
Loxapine HUMAN PRESCRIPTION DRUG LABEL 1 70518-1896 CAPSULE 25 mg ORAL ANDA 20 sections